One of the most misunderstood provisions in the entire tax code, the Qualified Small Business Stock (QSBS) has been around for more than 30 years. Yet it remained largely dormant — until now.

The QSBS is “unlike anything in the code,” says Shahrooz Shahnavaz, a tax partner at McGuireWoods.

In this conversation with colleague and host Geoff Cockrell, Shahrooz reviews the history of this unique benefit and puts it into context for today’s M&A deal-makers. Tune in for his insights on the potential 100% exclusion of gain, the structural limits that bar some professions — including healthcare — from qualifying, and the One Big Beautiful Bill Act’s “generous” $15 million per-shareholder, per-company cap.

Kain Capital has announced its acquisition of White Wilson Medical Center.

White Wilson, founded in 1946 and based in Fort Walton Beach, Florida, is an independent multi-specialty physician group which services Florida’s Emerald Coast. The practice operates nine clinic locations with more than 70 providers.

Kain, founded in 2014 and based in New York, is a private equity firm focused on investments in healthcare services and healthcare technology.

Terms of the acquisition were not disclosed.

Palladium Equity Partners has announced it will acquire a majority equity interest in DME Express from WayPoint Capital Partners.

DME Express, founded in 2006 and based in The Woodlands, Texas, is a provider of durable medical equipment (DME) serving hospice providers across the United States.

Palladium, founded in 1997 and based in New York, is a middle market private equity firm focused on companies in the U.S. Hispanic market, founder- and family-owned businesses, and companies with accretive M&A opportunities. The firm typically invests $50 million to $150 million of equity capital in companies with EBITDA between $10 million and $75 million, primarily in healthcare and select other sectors.

WayPoint, founded in 2004 and based in Stamford, Connecticut, is a private equity firm focused on lower middle market investments in healthcare services and industrials. The firm pursues control buyout of founder- and family-owned businesses with $5 million to $25 million in EBITDA. WayPoint will maintain a minority equity interest in DME Express following the transaction.

Terms of the transaction were not disclosed.

In this episode of the Becker Private Equity & Business Podcast, Holly Buckley, chair of the McGuireWoods’ healthcare department, discusses how the healthcare private equity landscape is evolving, with a sharper focus on discipline, shifting sector dynamics, and the key forces driving deal activity today. She also shares a preview of the firm’s Healthcare Private Equity Conference, taking place in Chicago on April 29–30, 2026.

BV Investment Partners has announced it has made a majority investment in Moxe Health. 

Moxe, founded in 2012 and based in Madison, Wisconsin, is a clinical data exchange platform, supporting the exchange of information between healthcare providers and health plans through integration within EHRs. 

BV, founded in 1983 and based in Boston, is a middle market private equity firm focused on tech-enabled business services and IT. The firm invests a minimum of $65 million for majority or minority positions in North American companies with average EBITDA between $7 million and $30 million.

Terms of the investment were not disclosed.

Chicago Pacific Founders (CPF) has announced an investment in Nexben.

Nexben, founded in 2015 and based in Grand Rapids, Michigan, is a fintech company that provides plan administration and payment solutions for the benefits industry.

CPF, founded in 2014 and based in Chicago and San Francisco, is a private equity firm focused on investing in growth companies within value-based care, healthcare services, AI and tech-enabled services, and caring for aging populations.  

Terms of the investment were not disclosed.

Home and alternate-site infusion therapy is a highly fragmented market. Just two large players command 35% to 40% market share while more than 800 smaller providers making up the remainder. And that fragmentation is exactly what’s drawing private equity interest.

Don Hooker, director of research at Bourne Partners, a leading life science investment firm, joins McGuireWoods partner and host Geoff Cockrell to unpack the investment landscape. Don explains that delivering drugs at home or in alternate sites can cost roughly half as much as treatment in an inpatient setting. He also outlines the two main pressures shaping the home infusion space.

Tune in for his insights about reimbursement dynamics, labor intensity, drug pricing and “back-end” strategic buyers such as Option Care Health.